Hormones, immune response, and pregnancy in healthy women and SLE patients

Swiss Medical Weekly

Volumn 140, Issue 13-14, 2010, Pages 187-201

  Zen, Margherita ^a   Ghirardello, Anna ^a   Iaccarino, Luca ^b   Tonon, Michele ^a   Campana, Carla ^a   Arienti, Silvia ^a   Rampudda, Mariaelisa ^a   Canova, Mariagrazia ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

Author keywords

Autoimmunity; Cytokines; Pregnancy; Sex hormones; Systemic lupus erythematosus

Indexed keywords

16ALPHA HYDROXYESTRONE; CARDIOLIPIN ANTIBODY; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; COPPER INTRAUTERINE DEVICE; DOUBLE STRANDED DNA ANTIBODY; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; FAS LIGAND; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PRASTERONE SULFATE; PREDNISONE; PROGESTERONE; PROLACTIN; PROLACTIN RECEPTOR; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG SAFETY; ENDOCRINE CELL; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPERPROLACTINEMIA; HYPOCOMPLEMENTEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; KLINEFELTER SYNDROME; LEUKOCYTE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOPOIESIS; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE; PREGNANCY; PREGNANCY OUTCOME; PROGESTERONE BLOOD LEVEL; PUERPERIUM; RELAPSE; REVIEW; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TROPHOBLAST; URINARY EXCRETION;

EID: 77950822386     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (222)

1. l Eskandari F, Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther. 2003;5:251-265 (Pubitemid 37407974)
2. Szyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoen- feld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: A basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am. 2005;31:161-175 (Pubitemid 40082060)
3. 3Medzhitov R, Janeway C Jr.Innate immunity. N Engl J Med. 2000;343:338-344 (Pubitemid 35454184)
4. Turrin NP, Rivest S. Unraveling the molecular details involved in the intimate link between the immune and neuroendocrine systems. Exp Biol Med. 2004;229:996-1006 (Pubitemid 39431079)
5. 5Francis K, Lewis BM, Akatsu H, Monk PN,Cain SA, Scanlon MF,et al. Complement C3a receptors in the pituitary gland: A novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J. 2003;17:2266-2268 (Pubitemid 39561461)
6. 6Tanriverdi F, Silveira LF,MacColl GS, Bouloux PM. The hy- pothalamic-pituitary-gonadal axis: Immune function and au- toimmunity. JEndocrinol. 2003;176:293-304 (Pubitemid 36410413)
7. 7Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus ery- thematosus. Clin Exp Rheumatol. 2008;26(3):436-441 (Pubitemid 352003212)
8. 8Sanchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Díaz J, Moreno-Coutiño G, Cravioto MC. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus. Am JMed. 2001;11:464-468 (Pubitemid 33016418)
9. 9Doria A, Cutolo M, Ghirardello A, Zampieri S, Vescovi F, Sulli A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum. 2002;47:202-209 (Pubitemid 34303848)
10. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Re- prod Toxicol. 2006;22(2):234-241 (Pubitemid 43994383)
11. Doria A, Ghirardello A, laccarino L, Zampieri S, Punzi L, Tar- ricone E, et al. Pregnancy,cytokines and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2004;51:989-995 (Pubitemid 39648193)
12. VerthelyiD. Sex hormones as immunomodulatorsinhealth and disease. Int Immunopharmacol. 2001;1:983-993
13. Straub RH.The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521-574
14. Straub RH, Cutolo M. Involvement of the hypothalamic-pituitary-adrenal/ gonadal axis and the peripheral nervous system in rheumatoid arthritis: Viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 2001;44:493-507. (Pubitemid 32234605)
15. Shames RS. Genderdifferencesinthedevelopmentandfunction of the immune system. J Adolesc Health. 2002;30(suppl):59-70.
16. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive Bcells. CurrTopMicrobiol Immunol. 2006;305:67-88. (Pubitemid 47400265)
17. Peeva E, Zouali M. Spotlight on the role ofhormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett. 2005;101:123-143 (Pubitemid 41368071)
18. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109:1625-1633 (Pubitemid 34663525)
19. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci. USA 2000;97:2703-2708 (Pubitemid 30159235)
20. Kincade PW, Medina KL, Payne KJ,Rossi MI, Tudor KS, Ya- mashita Y, et al. Early B-lymphocyte precursors and their regulation bysex steroids. Immunol Rev. 2000;175:128-137
21. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol. 2006;176:2703-2710 (Pubitemid 43306928)
22. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2:777-780
23. Hughes GC, Clark EA. Regulation of dendritic cells by female sexsteroids: relevance to immunityand autoimmunity.Autoim- munity. 2007;40:470-481
24. Monrad S, Kaplan MJ. Dendritic cells and the immuno- pathogenesis of systemic lupus erythematosus Immunol Res. 2007;37(2):135-145 (Pubitemid 47344125)
25. Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL. 17beta-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J Immunol. 2008;180(3): 1423-31.
26. Cutulo M, Capellino S, Montagna P, Ghiorzo P, Sulli A, Villaggio B. Sex hormones modulation of cell growth and apopto- sis of the human monocytic/macrophage cell line. Arthritis Res Ther. 2005;7:R1124-32.
27. Matthews J, Gustafsson JA.Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003;3(5):281-292
28. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006;27:299-402. (Pubitemid 44255847)
29. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol. 2003;38:13-22.
30. Doria A, Iaccarino L, Sarzi-Puttini P, Ghirardello A, Zampieri S, Arienti S, et al. Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci. 2006;1069:247-256 (Pubitemid 43989867)
31. Weidler C, Härle P, Schedel J, Schmidt M, Schölmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion ofmitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol. 2004;31:489-494 (Pubitemid 38337606)
32. Bernier MO, MikaeloffY, Hudson M, Suissa S. Combined oral contraceptive use and the risk of Systemic Lupus erythematosus. Arthritis Rheum. 2009;61:476-481
33. Sanchez-Guerrero J, Karlson EW, Liangn MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997;40:804-808 (Pubitemid 27199994)
34. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-433
35. Meier CR, Sturkenboom MS, Cohen AS. Postmenopausal estrogen replacement therapy and the risk ofdeveloping systemic lupus erythematosus. JRheumatol. 1998;25:1515-1519 (Pubitemid 28364755)
36. Jungers P, Liote F, Dehaine V, Dougados M, Viriot J, Pelissier C, et al. Hormonal contraception and lupus. Ann Med Interne. (Paris) 1990;141(3):253-256
37. Julkunen HA. Oral contraceptives in systemic lupus erythema- tosus: side-effects and influence on the activity of SLE. Scand J Rheumatol. 1991;20:427-433
38. Sänchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Menopause hormonal therapy in women with systemic lupus erythematosus Arthritis Rheum. 2007;56(9):3070-3079 (Pubitemid 47502754)
39. Arden NK, Lloyd ME, Spector TD, Hughes GR. Safetyofhormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus. 1994;3:11-13
40. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol. 1997;24:2149-2152 (Pubitemid 27474035)
41. Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safetyofhormonalreplacementtherapyinpostmenopausalpa- tients with systemic lupus erythematosus. Scand J Rheumatol. 1998;27:342-346 (Pubitemid 28480223)
42. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, etal. OC-SELENATrial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-2558 (Pubitemid 41785892)
43. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza- Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl JMed. 2005;353:2539-2549 (Pubitemid 41785891)
44. BuyonJP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized Trial. Ann Intern Med. 2005;142:953-962 (Pubitemid 40840309)
45. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti double stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1999;42:328-337 (Pubitemid 29072851)
46. Vidaver R. Molecular and clinical evidence of the role of estrogen in lupus. Trends Immunol. 2002;23:229-230 (Pubitemid 34499552)
47. Cohen-Solal JF, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, Diamond B. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus. 2008;17(6):528-532 (Pubitemid 351955427)
48. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol. 2001;167:1886-1890 (Pubitemid 32747492)
49. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen induced B cell maturation but not survival. J Immunol. 2005;175:1415-1423 (Pubitemid 41023040)
50. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462
51. Evans MJ, MacLaughlin S, Marvin RD, Abdou NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF alpha production in SLE but not in normal cultures. Clin Immunopathol. 1997;82:258-262 (Pubitemid 27128312)
52. Li J, McMurray RW. Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/ NZWF1 mouse model. Clin Immunol. 2007;123(2):219-226 (Pubitemid 46591958)
53. Bynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB xNZW) F1 mice. Genes Immun. 2008;9(2):137-152
54. Inui A, Ogasawara H, Naito T, Sekigawa I, Takasaki Y, Hayash- ida Y, et al. Estrogen receptor expression by peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Clin Rheumatol. 2007;26:1675-1678
55. Rider V, Li X, Peterson G, Dawson J, Kimler BF, Abdou NI. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol. 2006;33(6):1093-1101 (Pubitemid 43825458)
56. PhielKL, HendersonRA, AdelmanSJ, EllosoMM.Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97:107-113 (Pubitemid 40038861)
57. Kassi EN, Vlachoyiannopoulos PG, Moutsopoulos HM, Sekeris CE, Moutsatsou P. Molecular analysis of estrogen receptor alpha and beta in lupus patients. Eur J Clin Invest. 2001;31:86-93. (Pubitemid 32151126)
58. Johansson M, Arlestig L, Moller B, Smedby T, Rantapaa-Dahlqvist S. Oestrogen receptor alpha gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1611-1617 (Pubitemid 41532046)
59. Lee YJ, Shin KS, Kang SW, Lee CK, Yoo B, Cha HS, et al. Association of the oestrogen receptor alpha gene polymorphisms with diseaseonset in systemic lupus erythematosus. Ann Rheum Dis. 2004;63:1244-1299 (Pubitemid 39273502)
60. Kassi E, Vlachoyiannopoulos PG, Kominakis A, Kiaris H, Moutsopulos HM, Moutsatsou P. Estrogen receptors alpha gene polymorphism and systemic lupus erythematosus: A possible risk? Lupus. 2005;14:391-398 (Pubitemid 40756449)
61. Lu ZM, Wang ZE, Liu YQ, WuCX, Wang CY, Zhang BC, et al. Association of Estrogen Receptor Gene Polymorphisms with Cytokine Genes Expression in Systemic Lupus Erythematosus. Croat Med J. 2009;50:117-123
62. Barrett C, Neylon N, Snaith ML. Oestrogen-induced systemic lupus erythematosus. Br JRheumatol. 1986;25:300-301 (Pubitemid 16037879)
63. Pozzilli C, Falaschi P, Mainero C, Martocchia A, D'Urso R, Proietti A, et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology. 1999;53:622-624 (Pubitemid 29382062)
64. Yell JA, Burge SM. The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br JDermatol. 1993;129:18-22.
65. OskayT, KutluayL, Kaptanoglu A, Karabacak O. Autoimmune progesterone dermatitis. Eur J Dermatol. 2002;12:589-591 (Pubitemid 35440804)
66. De León-Nava MA, Nava K, Soldevila G, López-Griego L, Chévez-Ríos JR, Vargas-Villavicencio JA, et al. Immune sexual dimorphism: Effect ofgonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation J Steroid Biochem Mol Biol. 2009;113:57-64.
67. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Sampognaro S. Progesterone favors the development of hu- manThelper cell producing Th-2 type cytokines and promotes both IL-4 production and membrane CD expression in established Th1 cellclones. J Immunol. 1995;155:128-133
68. Canellada A, Blois S, Gentile T, Margni RA. In vitro modulation of protective antibody responses by estrogen, progesterone and interleukin-6. Am J Reprod Immunol. 2002;48: 333-343 (Pubitemid 35252027)
69. Szekeres-Bartho J, Wilczynski JR, Basta P, Kalinka J. Role of progesterone and progestin therapy in threatened abortion and preterm labour. Front Biosci. 2008;13:1981-1990 (Pubitemid 351599750)
70. Dosiou C, Lathi RB, Tulac S, Huang ST, Giudice LC. Inter- feron-related and other immune genes are downregulated in peripheral blood leukocytes in the luteal phase of the menstrual cycle. J Clin Endocrinol. 2004;89:2501-2504 (Pubitemid 38619896)
71. Szekeres-Bartho J, Polgar B, Kozma N, Miko E, Par G, Sze- reday L, et al. Progesterone-dependent immunomodulation. Chem Immunol Allergy. 2005;89:118-125 (Pubitemid 43154890)
72. Szereday L, Varga P, Szekeres-Bartho J. Cytokine production in pregnancy.Am J Reprod Immunol. 1997;38:418-422
73. Cutolo M, Sulli A, Seriolo S, Accardo S, Masi AT.Estrogens, the immune response, and autoimmunity.Clin Exp Rheumatol. 1995;13:217-226
74. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli GF, Roma- gnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med. 1998;4:1020-1024 (Pubitemid 28417333)
75. Charnock-Jones DS, Sharkey AM, Fenwick P, Smith SK. Leukemia inhibitory factor mRna concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRna for the receptor at this time. J Reprod Fertil. 1994;101:421-426 (Pubitemid 24233801)
76. Piccinni MP, Scaletti C, Vultaggio A, Maggi E, Romagnani S. Defective production of LIF, M-CSF and Th2-type cytokines by T cells at fetomaternal interface is associated with pregnancy loss. J Reprod Immunol. 2001;52:35-43. (Pubitemid 32916377)
77. Canellada A, Alvarez I, Berod L, Gentile TJ.Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells. Steroid Biochem Mol Biol. 2008;111(3-5):255-261
78. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci. USA. 2003;100:2237-2242 (Pubitemid 36297483)
79. Dosiou C, Hamilton AE, Pang Y, Overgaard MT, Tulac S, Dong J, et al. Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J Endocrinol. 2008;196(1): 67-77. (Pubitemid 351234572)
80. Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, et al. Depletion of CD8C cells abolishes the pregnancy protective effect of progesterone substitution with dydroges- terone in mice by altering the Th1/Th2 cytokine profile. J Immunol. 2004;172:5893-5899 (Pubitemid 38621187)
81. Vogl D, Falk W Dorner M, Scholmerich J, Straub RH. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. J Rheumatol. 2003;30:269-275 (Pubitemid 36152588)
82. Benito Urbina S, Harte LE, Gijon BJ, Arnalich FF. Hormonal changes in fertile women with quiescent systemic lupus erythematosus. An Med Int. 1995;12:221-224
83. Medeiros PB, Febrônio MV, Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus Lupus. 2009;18:38-43.
84. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmunity Rev. 2007;6:537-542 (Pubitemid 47374609)
85. Mc Murray RW. Estrogen, prolactin and autoimmunity: actions and interactions. Int Immunopharmacol. 2001;1:995-1008.
86. Matalka KZ. Prolactin enhances production of interferon-g, interleukin-12, and interleukin-10, but not of tumor necrosis factor-a in a stimulus-specific manner.Cytokine. 2003;21:187-194
87. Matera L, Contarini M, Bellone G, Forno B, Biglino A. Up- modulation of interferon-g mediates the enhancement of spontaneous cytotoxicity in prolactin-activated natural killer cells. Immunology. 1999;98:386-392 (Pubitemid 29526961)
88. Yu-Lee LY.Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435-455
89. Matera L, Galetto A, Geuna M, Vekemans K, Ricotti E, Contarini M, et al. Individual and combined effect of gran- ulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology. 2000;100:29-36. (Pubitemid 30242879)
90. Chavez-Rueda K, Hernandez J, Zenteno E, Leanos-Miranda A, Legorreta-Haquet MV, Blanco Favela F. Identification of prolactin as a novel immunomodulator on the expression of costimulatory molecules and cytokine secretions on T and B human lymphocytes. Clin Immunol. 2005;116:182-191 (Pubitemid 40910244)
91. Chavez-Rueda K, Legorreta-Haquet MV, Cervera-Castillo H, Sanchez L, Jara LJ, Zenteno E, et al. Prolactine effect on CD69 and CD154 expression by CD4p cells from systemic lupus erythematosus patients. Clin Exp Rheumatol. 2005;23:769-777 (Pubitemid 43040503)
92. Takizawa K, Kitani S, Takeuchi F, Yamamoto K. Enhanced expression of CD69 and CD25 antigen on human peripheral blood mononuclear cells by prolactin. Endocr J. 2005;52: 635-641 (Pubitemid 41609056)
93. Matera L, Mori M, Galetto A. Effect of prolactin on antigen presenting function of mononocyte derived dendritic cells. Lupus. 2001;10:728-734 (Pubitemid 33041665)
94. Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J Clin Invest. 2003;111:275-283 (Pubitemid 36105927)
95. De León-Nava MA, Morales-Montor J. Immune sexual dimorphism: can sex steroids affect the Th1/Th2 cytokine profile? Rev Invest Clin. 2006;58:161-169 (Pubitemid 44018154)
96. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoim- munity.Autoimmun Rev. 2002;1:360-364 (Pubitemid 38340249)
97. Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R. Modulation of prolactin expression in human T lymphocytes by cy- tokines. JNeuroimmunol. 2005;162:190-193 (Pubitemid 40503114)
98. Walker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann N Y Acad Sci. 1998;840:762-772 (Pubitemid 28302102)
99. Elbourne KB, Keisler D, McMurray RW.Differential effects ofestrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus. Lupus. 1998;7:420-427 (Pubitemid 28410189)
100. Leanos-Miranda A, Cardenas-Mondragon G. Serum free prolactin concentrations in patients with systemic lupus ery- thematosus are associated with lupus activity.Rheumatology. 2006;45:97-101. (Pubitemid 43033883)
101. Garcia M, Colombani-Vidal ME, Zylbersztein CC, Testi A, Marcos J, Arturi A, et al. Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus. Lupus.2004;13:575-583 (Pubitemid 39145486)
102. Mendez I, Alcocer-Varela J, Parra A, Lava-Zavala A, De la Cruz DA, Alarcon-Segovia D, et al. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: A possible role of lymphocyte-derived prolactin. Lupus. 2004;13:45-53. (Pubitemid 38129350)
103. Vera-Lastra O, Mendez C, Jara LJ, Cisneros M, Medina G, Ariza R, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol. 2003;30:2140-2146 (Pubitemid 37221842)
104. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26:951-968
105. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus-association with disease activity.J Rheumatol. 2001;28:2216-2221 (Pubitemid 32947865)
106. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001;10:554-561 (Pubitemid 32777652)
107. Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, Blanco- Favela F. Antiprolactin autoantibodies in systemic lupus erythematosus: Frequency and correlation with prolactinemia and disease activity.J Rheumatol. 2001;28:1546-1553 (Pubitemid 32660626)
108. Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun Rev.2008;7: 251-255
109. Kocar IH, Yesilova Z, Ozata M, Turan M, Sengul A, Ozdemir I. The effect of testosterone replacement treatment on im- munological features ofpatients with Klinefelter s Syndrome. Clin Exp Immunol. 2000;121:448-452
110. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: Their role in inflammatory, aller- gic and immunological disorders. Curr Drug Targets Inflamm Allergy. 2005;4:377-385
111. Petri M. Sexhormones and systemic lupus erythematosus Lupus. 2008;17:412-415
112. Zietz B, Reber T, Oertel M, Gluck T, Scholmerich J, Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehy- droepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol. 2000;27:911-918 (Pubitemid 30389746)
113. Verthelyi D, Petri M, Ylamus M, Klinman DM. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus. 2001;10:352-358 (Pubitemid 32536658)
114. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50:2858-2868
115. Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. GL601 Study Group. Effects ofpras- terone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46:1820-1829 (Pubitemid 34774514)
116. Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. Ann Rheum Dis. 2004;63:1623-1626 (Pubitemid 39573692)
117. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity.1998;8:275-283 (Pubitemid 28188888)
118. Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, et al. Signaling and transcription in T helper development. Annu RevImmunol. 2000;18:451-594. (Pubitemid 30365388)
119. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549 (Pubitemid 23161621)
120. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generationofIL-4producingcells. JExp Med. 1990;172:921-929 (Pubitemid 20301238)
121. Diehl S, Rincon M. The two faces ofIL-6 onTh1/Th2 differentiation. Mol Immunol 2002;39(9):531-536 (Pubitemid 35341492)
122. Sallusto F, Lanzavecchia A. Human Th17 cells in infection and autoimmunity. Microbes and Infect. 2009;11(5):620-624
123. Dong C. Regulation and pro-inflammatory function of inter- leukin-17 family cytokines. Immunol Rev. 2008;226:80-86
124. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effectorTcell trilogy.Curr Op Immunol. 2007;19:652-657 (Pubitemid 350236805)
125. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infect. 2009 Apr 14. [Epub ahead of print]
126. Chen Z, O'Shea JJ.Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008;41:87-102.
127. Takatori H, Kanno Y, Chen Z, O'Shea JJ.New complexities in helper T cell fate determination and the implications for autoimmune diseases Mod Rheumatol. 2008;18:533-541
128. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17- producing cells. Nat Rev Immunol. 2006;6:329-334
129. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467-476 (Pubitemid 39370503)
130. Huang SH, Huang SH, Frydas S, Kempuraj D, Barbacane RC, Grilli A, et al. Interleukin-17 and the interleukin-17 fam- ilymember network. AllergyAsthma Proc. 2004;25:17-21 (Pubitemid 38365562)
131. Happel KI, Dubin PJ, Zheng M, Ghiraldi N, Lockhart C, Quinton LJ, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med. 2005;202:761-769 (Pubitemid 41345965)
132. ChungY, Yang X, Chang SH, Ma L, Tian Q, Dong C. Expression and regulation of IL22 in the IL17-producing CD4+ T lymphocytes. Cell Res. 2006;16:902-907 (Pubitemid 44764200)
133. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunal. 2007;8:369-377 (Pubitemid 46745412)
134. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004;190:624-631 (Pubitemid 38982105)
135. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement ofthe IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967-974 (Pubitemid 47300011)
136. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484-487 (Pubitemid 47123515)
137. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007; 448(7152):480-483 (Pubitemid 47123514)
138. Dong C. Regulation and pro-inflammatory function of inter- leukin-17 family cytokines. Immunol Rev. 2008;226:80-86
139. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson Co, et al. Transforming growth factor- beta induces development of the TH17 lineage. Nature. 2006;441:231-234
140. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sal- lusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of inter- leukin 17-producing human T helper cells. Nat Immunol 2007;8:942-949 (Pubitemid 47300008)
141. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Bas- ham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233-240
142. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features ofhuman Th17 cells. JExp Med. 2007;204:1849-1861
143. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4|) effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. NatImmunol. 2005;6(11):1123-1132
144. Hunter CA. New IL-12-family members: IL-23 and IL- 27, cytokines with divergent functions. Nat Rev Immunol. 2005;5(7):521-531
145. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis Rheumatology (Oxford). 2009;48(6):602-6.
146. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis ofT cell-mediated tissue damage. Nat Med. 2007;13:139-145
147. KiklyK, Liu L, Na S, Sedgwick DJ.The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18:670-675
148. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141
149. Ma HL, Liang S, Li J, Nepierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597-607.
150. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423-7430
151. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146-155
152. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin 17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58:875-887
153. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers ofcirculating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307-2317
154. Eyerich K, Pennino D, Scarpon C, Foerster S, Nasorri F, Behrendt H, et al. IL-17 in atopic eczema: Linking allergen- specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol. 2008;23:59-66.
155. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrateautoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008;9:166-175
156. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.Clin Immunol. 2008;127: 385-393
157. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2009 published online: 04 April 2009.
158. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and Natural Treg Cell population Dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472-1483
159. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative t cells in patients with SLE produce IL-17. J Immunol. 2008;181:8761-8766
160. Doreu A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell- activating factor to influence B cell biology and the pathophysiology of systemic lupus erythemathosus. Nat Immunol. 2009;10(7):778-785
161. Dong GF, Ye RG, Shi W Liu S, Wang T, Yang X, et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J. (Engl) 2003;116:543-548
162. Branch DW.Physiologic Adaptation of pregnancy.Am J Reprod Immunol. 1992;28: 120-128
163. McMurray RW.Steroid hormones in lupus pregnancy: in control? Arthritis Rheum. (Arthritis Care Res) 2002;47: 116-117
164. Jara-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol. 1991;18:349-353
165. Wood GW.Is restricted antigen presentation the explanation offetal allograft survival? Immunol Today. 1994;15:15-18
166. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. JImmunol. 2003;171:1376-1384
167. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005;19 681-693
168. Ishitani A, Sageshima N, Hatake K. The involvement ofHLA- E and -F in pregnancy. JReprod Immunol. 2006;69:101-113
169. Tabiasco J, Rabot M, Aguerre-Girr M, El Costa H, Berrebi A, Parant O, et al. Human decidual NK cells: unique phenotype and functional properties- a review.Placenta. 2006;27(suppl A):S34-9.
170. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Green field C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. NatMed. 2006;12:1065-1074
171. Sakata KM, Sakata A, Kong L, Dang H, Talal N. Role of Fas/ FasL interaction in physiology and pathology: The good and the bad. Clin Immunol Immunopathol. 1998;87:1-7.
172. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Bailliere's Clin Obstet Gynaecol. 1992;6:439-460
173. Lin H, Mosman TR, Guilbert L, Tntipopipats S, Wegmann TG.Syntesisof Thelper-2-cytokinesatthematernal-fetalinterface. JImmunol. 1993;151:4562-4573
174. Kanik KS, Wilder RL. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy.Rheum Dis Clin North Am. 2000;26 805-823
175. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in thematernal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today. 1993;14:353-356
176. Orsi NM. Cytokine networks in the establishment and maintenance of pregnancy.Hum Fertil. (Camb) 2008;11(4): 222-230
177. Orsi NM, Tribe RM. Cytokine Networks and the regulation of uterine function in pregnancy and parturition. J Neuroendocr. 2008;20:462-469
178. Hannan NJ, Salamonsen LA. Role of chemokines in the en- dometrium and in embryo implantation. Curr Opin Obstet Gynecol. 2007;19:266-272
179. Lim KJH, Odukoya OA, Ajjan RA, Li TC, Weetman AP, Cooke ID.Profile of cytokine mRNA expression in periimplantation human endometrium. Mol Hum Reprod. 1998;4:77-81.
180. Chow SS, Craig ME, Jones CA, Hall B, Catteau J, Lloyd AR, et al. Differences in amniotic fluid and maternal serum cy- tokine levels in early midtrimester women without evidence ofinfection. Cytokines. 2008;44(1):78-84.
181. Sacks GP, Clover LM, Bainbridge DR, Redman CW, Sargent IL. Flow cytometric measurement of intracellular Th1 and Th2 cytokine production by human villous and extravillous cytotrophoblast. Placenta. 2001;22:309-318
182. HannaN, Hanna I, Hleb M, Wagner E, Dougherty J, Balkundi D, et al. Gestational age-dependent expression of IL-10 and its receptor in human placental tissues and isolated cytotrophoblasts. JImmunol. 2000;164:5721-5728
183. Ostojic S, Dubanchet S, Abdelkarim M, Truyens C, Capron F, Chaouat G. Demonstration of the presence of the IL-16 and IL-17 and IL-18 at the feto maternal interface during murine pregnancy.Am JReprod Immunol. 2003;49(2):101-112
184. Pongcharoen S, Somran J, Sritippayawan S, Niumsup P, Chanchan P, Butkhamchot P, et al. Interleukin-17 Expression in the Human Placenta. Placenta. 2007;28:59-63.
185. Halonen M, LohmN IC, Stern DA, Spangenberg A, Anderson D, MobleyS. Th1/Th2 Patterns and Balance in Cytokine Production in the Parents and Infants of a Large Birth Cohort J Immunol. 2009;182:3285-3293
186. Ostensen M, Forger F, Villiger P. Cytokines and pregnancyin rheumatic disease. Ann NY Acad Sci. 2006;1069:353-363
187. Kupferminc M, Peaceman A, Aderka D. Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid.Am J Obstet Gynecol. 1995;173:900-905
188. Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, et al. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand. 2001;80:602-608
189. Bahar A, Ghalib H, Moosa RA, Zaki ZM, Thomas C, Nabri OA.Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-α and interferon- γ in preterm labor.Acta Obstet Gynecol Scand. 2003;82:543-549
190. Jonsson Y, Ruber M, Matthiesen L, Berg G, Nieminen K, Sharma S, et al. Cytokine mapping sera from women with preeclampsia and normal pregnancies. J Reprod Immunol. 2006;70:83-91.
191. Brewster JA, Orsi NM, Gopichandran N, McShane P, Ekbote UV Walker JJ.Gestational effects on host inflammatory response in normal and pre-eclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol. 2008;140:21-26
192. Brewster JA, Orsi NM, Gopichandran N, McShane P, Ekbote UV, Walker JJ.Host inflammatory response profiling in preeclampsia using an in vitro whole blood stimulation model. Hypertens Pregnancy. 2008;27:1-16.
193. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF III, Petraglia F. Inflammation and Pregnancy.Reprod Sci. 2009;16(2):206-215
194. Goldenberg RL, Goepfert AR, Ramsey PS. Biochemical markers for the prediction of preterm birth. Am J Obstet Gynecol. 2005;192:S36-46.
195. Daher S, Shulzhenko N, Morgun A, Mattar R, Rampim GF, Camano L, et al. Associations between cytokine gene polymorphisms and recurrent pregnancyloss. J Reprod Immunol. 2003;58:69-77.
196. Jasper MJ, Tremellen KP, Robertson SA. Reduced expression of IL-6 and IL-1alpha mRNAs in secretory phase en- dometrium of women with recurrent miscarriage. J Reprod Immunol. 2007;73:74-84.
197. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy.Semin Immunopathol. 2007;29:185-191
198. Ostensen M, Forger F, Villiger PM. Cytokines and pregnancy in rheumatic disease. Ann N YAcad Sci. 2006;1069:353-363
199. Munoz-Valle JF, Vazquez-Del Mercado M, Garcia-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martínez-Bonilla G, et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol. 2003;131:377-384
200. Ætensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, et al. Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology. (Oxford) 2008;47:iii28-31.
201. Petri M. Prospective study of systemic lupus erythematosus pregnancies. Lupus. 2004;13:688-689 (Pubitemid 39279785)
202. Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies. Rheumatology. (Oxford) 2008;47:iii9-12.
203. Tincani A, Faden D, Biasini-Rebaioli C. Pregnancy in SLE (2): is it possible to predict gestational outcome? Arthritis Rheum. 2002;812:S322.
204. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther.2006;8(3):209 [Epub ahead of print].
205. Petri M, Howard D, Repke J. Frequency of lupus flares in pregnancy.The Hopkins Lupus Pregnancy Center experience. Arthris Rheum. 1991;34:1538-1545
206. Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancy. Br. J Rheumatol. 1996;35:133-138
207. Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-525
208. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52:514-521
209. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum. 1993;36:1392-1397
210. Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum. 2004;50:3941-3946
211. Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum. 1989;32:665-670
212. Meehan RT, Dorsey JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol. 1987;14:252-258
213. Richaud-Patin Y, Alcocer-Varela J, Llorente L. High levels of Th2 cytokines gene expression in systemic lupus erythematosus. Rev Invest Clin. 1995;47:267-272
214. Tincani A, Bompane D, Danieli E, Doria A. Pregnancy, lupus and antiphosphpolipid syndrome (Huges syndrome). Lupus. 2006;15:156-160
215. Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol. 1996;27(2):201-206
216. Benirschke K, Kauffman P. Lupus erythematosus and lupus anticoagulant. In: Benirschke K, Kauffman P, editors. Pathology of the human placenta. 3rd ed. New York: Springer-Verlag; 1995. p. 512-520
217. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119: 1497-1499
218. Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghi- rardello A, Zampieri S, Gambari PF, Perini G. Health-related quality oflife in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact ofage. Rheumatology. 2004;43:1574-1579
219. Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, Zampieri S, Della Libera S, Perini G, Todesco S. Health-related qualityoflife in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants. Rheumatology. 2004;43:1580-1586
220. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview.Autoimmunity. 2005;38:465-472 (Pubitemid 43101780)
221. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis - Basic mechanisms. Rheum Dis Clin N Am. 2005;31:329-354
222. Ghirardello A, Doria A, Zampieri S, Tarricone E, Tozzoli R, Villalta D, et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmunity. 2004;22:235-240